Gossamer Bio Files 8-K Report

Ticker: GOSS · Form: 8-K · Filed: 2025-06-16T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, corporate-filing, regulation-fd

TL;DR

Gossamer Bio filed an 8-K on 6/16/25, standard corporate update, no major news yet.

AI Summary

On June 16, 2025, Gossamer Bio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, with no specific financial figures or new material events detailed in the provided text. The report confirms the company's identity, incorporation in Delaware, and principal executive offices in San Diego, California.

Why It Matters

This 8-K filing serves as a public notification of corporate events, though the provided excerpt does not detail specific material changes or financial updates for Gossamer Bio, Inc.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report without disclosure of significant new risks or material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Gossamer Bio, Inc.?

The filing is primarily for Regulation FD Disclosure and to report on Other Events, as indicated in the Item Information section.

On what date was this 8-K report filed or effective?

The report was filed as of June 16, 2025, and the date of the earliest event reported is also June 16, 2025.

Where are Gossamer Bio, Inc.'s principal executive offices located?

Gossamer Bio, Inc.'s principal executive offices are located at 3115 Merryfield Row, Suite 120, San Diego, California, 92121.

Under which section of the Securities Exchange Act of 1934 is this 8-K filed?

This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is Gossamer Bio, Inc.'s IRS Employer Identification Number (EIN)?

Gossamer Bio, Inc.'s IRS Employer Identification Number is 47-5461709.

From the Filing

0001728117-25-000040.txt : 20250616 0001728117-25-000040.hdr.sgml : 20250616 20250616073112 ACCESSION NUMBER: 0001728117-25-000040 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250616 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250616 DATE AS OF CHANGE: 20250616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gossamer Bio, Inc. CENTRAL INDEX KEY: 0001728117 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 475461709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38796 FILM NUMBER: 251048535 BUSINESS ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 684-1300 MAIL ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 goss-20250616.htm 8-K goss-20250616 0001728117 FALSE 0001728117 2025-06-16 2025-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter)   Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       3115 Merryfield Row, Suite 120 San Diego , California , 92121 (Address of Principal Executive Offices) (Zip Code) ( 858 ) 684-1300 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   GOSS   Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ Item 7.01 Regulation FD Disclosure. On June 16, 2025, Gossamer Bio, Inc. (the “Company”) issued a press release reporting the completion of enrollment for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III pulmonary arterial hypertension (PAH) patients discussed in Item 8.01 below. The full text of the press release is attached as Exhibit 99.1 to this Current Report. The information contained in this Item 7.01, including in Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorp

View on Read The Filing